Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Recommendation of “Buy” from Brokerages

Bicara Therapeutics Inc. (NASDAQ:BCAX) has received an average recommendation of “Buy” from the eight analysts that are covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $36.50.

A number of equities analysts have weighed in on BCAX shares. Wedbush reissued an “outperform” rating and issued a $31.00 price objective on shares of Bicara Therapeutics in a research report on Wednesday, February 12th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.01 price target on shares of Bicara Therapeutics in a research report on Thursday, March 13th. Finally, HC Wainwright increased their price objective on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, January 27th.

Institutional Investors Weigh In On Bicara Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Spire Wealth Management acquired a new position in shares of Bicara Therapeutics during the fourth quarter valued at about $31,000. BNP Paribas Financial Markets bought a new stake in Bicara Therapeutics during the fourth quarter worth about $32,000. Legal & General Group Plc bought a new stake in Bicara Therapeutics during the fourth quarter worth about $33,000. Summit Investment Advisors Inc. acquired a new position in shares of Bicara Therapeutics during the fourth quarter worth approximately $35,000. Finally, Virtus ETF Advisers LLC acquired a new position in shares of Bicara Therapeutics during the fourth quarter worth approximately $69,000.

Bicara Therapeutics Price Performance

BCAX stock opened at $13.50 on Tuesday. The business’s fifty day moving average price is $13.15. Bicara Therapeutics has a 52 week low of $11.10 and a 52 week high of $28.09.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.